ClinicalTrials.gg
Active, not recruitingNCT03964727TROPiCS-03Updated Apr 28, 2026Results posted

Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors

A Phase 2 interventional study of Sacituzumab Govitecan-hziy in Metastatic Solid Tumor, sponsored by Gilead Sciences. Active, not recruiting at 65 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-28.

Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
227
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,054 studies in Neoplasm Metastasis with a site in United States — 346 open to participants now, 542 under way, 58 of them phase 3. Neoplasm Metastasis · United States.

Enrollment
273rd of 1,863
227 · median 43
Started
2019
with 89 others
Phase 2
566 of 2,054
60 open now
Primary completion
2025-01
later than 49 of 540 live
Registered
1,332nd of 2,054
by date

Among the 2,054 studies in Neoplasm Metastasis with a site in United States, this one is the 273rd largest by enrollment of the 1,863 interventional ones that give a count, is one of 90 that started in 2019, is one of 566 in phase 2, reaches primary completion later than 49 of the 540 other live ones, and was the 1,332nd registered.

Neoplasm Metastasis

4,045 studies on the registry are indexed under Neoplasm Metastasis; 889 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

346 of the 2,054 studies in Neoplasm Metastasis with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 690 Neoplasm Metastasis studies recruiting now, 537 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,054 studies in Neoplasm Metastasis with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical study is to learn more about the study drug, sacituzumab govitecan-hziy, in participants with metastatic (cancer that has spread) solid tumors.

03

Conditions studied

  • Metastatic Solid Tumor

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Individuals with the following documented (M1, Stage IV) or locally advanced solid tumors

    • NSCLC [adenocarcinoma or squamous cell carcinoma (SCC)] that has progressed after prior platinum-based chemotherapy and programmed death-(ligand) 1 (PD-(L)1) directed therapy
    • HNSCC that has progressed after prior platinum-based chemotherapy and anti-PD-(L)1 directed therapy No more than 3 is allowed
    • Endometrial carcinoma that has progressed after prior platinum-based chemotherapy and anti-PD-(L)1 directed therapy No more than 3 prior lines of systemic treatment is allowed.
    • Extensive stage SCLC that has progressed after prior platinum-based chemotherapy and PD-(L)1 directed therapy. No more than one prior line of systemic treatment is allowed (re-challenge with the same initial regimen is not allowed)
  • (ECOG) Performance status score of 0 or 1
  • Adequate hematologic counts without transfusional or growth factor support within 2 weeks of study drug initiation
  • Adequate hepatic and renal function [ (CrCl) ≥30mL/min]
  • Individual must have at least a 3-month
  • Have by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) as per (RECIST) 1.1 criteria

Key Exclusion Criteria:

  • Have had a prior anti-cancer biologic agent within 4 weeks prior to study Day 1 or have had prior chemotherapy, targeted small molecule therapy, radiation therapy within 2 weeks prior to Study Day 1
  • Have not recovered (i.e., ≤ Grade 1) from adverse events due to a previously administered agent
  • Have previously received topoisomerase I inhibitors
  • Have an active second
  • Have known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Individuals with previously treated may participate provided they have stable CNS disease for at least 4 weeks prior to the first dose of study drug and all neurologic symptoms have returned to baseline, have no evidence of new or enlarging brain metastases and are taking ≤20 mg/day of prednisone or its equivalent. All individuals with carcinomatous meningitis are excluded regardless of clinical stability
  • Additional cohort specific exclusion criteria

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
227 participants (actual)

Study arms

  • Experimental
    Cohort 1 Group 1: NSCLC [Adenocarcinoma + Squamous Cell Carcinoma (SCC)]

    Based on protocol amendment 1, participants with non-small cell lung cancer (NSCLC) subtypes such as adenocarcinoma and SCC with high trophoblast cell-surface antigen 2 (Trop-2) expression will receive sacituzumab govitecan-hziy (SG) 10 mg/kg of body weight, administered as a slow intravenous (IV) infusion on Days 1 and 8 of a 21-day treatment cycle until progression of disease, unacceptable toxicity, study withdrawal, death, or another treatment discontinuation criteria will be met.

    Drug: Sacituzumab Govitecan-hziy

  • Experimental
    Cohort 1 Group 2: NSCLC (Adenocarcinoma)

    Based on protocol amendment 2 or 3, participants with NSCLC subtype of adenocarcinoma with or without high Trop-2 expression will receive SG 10 mg/kg of body weight, administered as a slow IV infusion on Days 1 and 8 of a 21-day treatment cycle until progression of disease, unacceptable toxicity, study withdrawal, death, or another treatment discontinuation criteria will be met.

    Drug: Sacituzumab Govitecan-hziy

  • Experimental
    Cohort 1 Group 3: NSCLC (SCC)

    Based on protocol amendment 2 or 3, participants with NSCLC subtype of SCC with or without high Trop-2 expression will receive SG 10 mg/kg of body weight, administered as a slow IV infusion on Days 1 and 8 of a 21-day treatment cycle until progression of disease, unacceptable toxicity, study withdrawal, death, or another treatment discontinuation criteria will be met.

    Drug: Sacituzumab Govitecan-hziy

  • Experimental
    Cohort 2: Head And Neck Squamous Cell Carcinoma (HNSCC)

    Participants with HNSCC will receive SG 10 mg/kg of body weight, administered as a slow IV infusion on Days 1 and 8 of a 21-day treatment cycle until progression of disease, unacceptable toxicity, study withdrawal, death, or another treatment discontinuation criteria will be met.

    Drug: Sacituzumab Govitecan-hziy

  • Experimental
    Cohort 3: Endometrial Cancer (EC)

    Participants with EC will receive SG 10 mg/kg of body weight, administered as a slow IV infusion on Days 1 and 8 of a 21-day treatment cycle until progression of disease, unacceptable toxicity, study withdrawal, death, or another treatment discontinuation criteria will be met.

    Drug: Sacituzumab Govitecan-hziy

  • Experimental
    Cohort 4: Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

    Participants with ES-SCLC will receive SG 10 mg/kg of body weight, administered as a slow IV infusion on Days 1 and 8 of a 21-day treatment cycle until progression of disease, unacceptable toxicity, study withdrawal, death, or another treatment discontinuation criteria will be met.

    Drug: Sacituzumab Govitecan-hziy

Interventions

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by Investigator's Assessment

    ORR was defined as the percentage of participants who had the best overall response of either complete response (CR) or partial response (PR). Responses are based on the investigator-assessed tumor response using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) criteria for each histologic cohort. CR: Disappearance of all target and non-target lesions; and normalization of tumor marker levels initially above upper limits of normal; PR: \>30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. The ORR rate was calculated with a two-sided exact 95% CI using the Clopper-Pearson method. Percentages are rounded off.

    Time frame: Cohort 1: Up to 5.3 years; Cohort 2: Up to 3.4 years; Cohort 3: Up to 3.3 years; Cohort 4: Up to 2.5 years

Secondary outcomes

  1. ORR According to RECIST 1.1 by Blinded Independent Central Review (BICR) Assessment

    ORR was defined as the percentage of participants who had the best overall response of either CR or PR. Responses are based on BICR assessment using RECIST 1.1 criteria for each histologic cohort. CR: Disappearance of all target and non-target lesions; and normalization of tumor marker levels initially above upper limits of normal; PR: \>30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD. The ORR rate was calculated with a two-sided exact 95% CI using the Clopper-Pearson method.

    Time frame: Cohort 1: Up to 5.3 years; Cohort 2: Up to 3.4 years; Cohort 3: Up to 3.3 years; Cohort 4: Up to 2.5 years

  2. Duration of Response (DOR) According to RECIST 1.1 by BICR Assessment

    DOR was the date of the first evaluation showing documented response, either PR or CR, to date of the first progression of disease (PD) or death from any cause,whichever comes first. Response are according to RECIST 1.1 by BICR for each histological cohort. CR: Disappearance of all target and non-target lesions; and normalization of tumor marker levels initially above upper limits of normal;PR: \>30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD. Disease progression was defined as an increase of \>20% in the sum of diameters of target lesions, taking as reference the smallest sum on study(this includes the baseline sum if that is the smallest on study). In addition, the sum must also demonstrate an absolute increase of more than 5 mm or the appearance of ≥ 1 new non-target lesions and/or unequivocal progression of existing non-target lesions. DOR was estimated using Kaplan-Meier estimate. The 95% CI was computed by Brookmeyer-Crowley method.

    Time frame: Cohort 1: Up to 5.3 years; Cohort 2: Up to 3.4 years; Cohort 3: Up to 3.3 years; Cohort 4: Up to 2.5 years

  3. Clinical Benefit Rate (CBR) According to RECIST 1.1 by BICR Assessment

    CBR was percentage of participants with best overall response of CR, PR,or durable stable disease (SD) (SD ≥ 6 months after first dose). Responses are according to RECIST 1.1 by BICR.CR: Disappearance of all target and non-target lesions;\& normalization of tumor marker levels initially above upper limits of normal;PR:\>30% decrease in sum of LD of target lesions, taking as reference the baseline sum LD. SD:Neither sufficient shrinkage for PR nor sufficient increase for PD, taking reference of smallest sum LD since treatment started or ≥ 1 non-target lesions with maintenance of tumor marker level above normal limits.PD: Increase of \>20% in sum of diameters of target lesions, taking reference of smallest sum(this includes baseline sum if smallest on study), the sum must also demonstrate an absolute increase of more than 5 mm or of ≥ 1 new non-target lesions and/or unequivocal progression of existing non-target lesions. Two-sided CI was based on Clopper-Pearson method.

    Time frame: Cohort 1: Up to 5.3 years; Cohort 2: Up to 3.4 years; Cohort 3: Up to 3.3 years; Cohort 4: Up to 2.5 years

  4. Progression-free Survival (PFS) According to RECIST 1.1 by BICR Assessment

    PFS was defined as the time from the first dose until objective tumor progression or death from any cause, whichever comes first. Responses are according to RECIST 1.1 by BICR. Disease progression was defined as an increase of \>20% in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition, the sum must also demonstrate an absolute increase of more than 5 mm or the appearance ≥ 1 new non-target lesions and/or unequivocal progression of existing non-target lesions. PFS was estimated using Kaplan-Meier estimate. The 95% CI for median was computed by Brookmeyer-Crowley method.

    Time frame: Cohort 1: Up to 5.3 years; Cohort 2: Up to 3.4 years; Cohort 3: Up to 3.3 years; Cohort 4: Up to 2.5 years

  5. DOR According to RECIST 1.1 by Investigator's Assessment

    DOR was the date of the first evaluation showing documented response, either PR or CR, to date of the first PD or death from any cause, whichever comes first. Responses are based on investigator-assessed tumor response by RECIST 1.1 criteria for each histological cohort.CR:Disappearance of all target and non-target lesions;and normalization of tumor marker levels initially above upper limits of normal;PR:\>30% decrease in the sum of the LD of target lesions,taking as reference the baseline sum LD. Disease progression was defined as increase of \>20% in sum of diameters of target lesions, taking as reference the smallest sum on study(this includes the baseline sum if that is the smallest on study).In addition, the sum must also demonstrate an absolute increase of more than 5 mm or the appearance of ≥ 1 new non-target lesions and/or unequivocal progression of existing non-target lesions. DOR was estimated using Kaplan-Meier estimate. The 95% CI was computed by Brookmeyer-Crowley method.

    Time frame: Cohort 1: Up to 5.3 years; Cohort 2: Up to 3.4 years; Cohort 3: Up to 3.3 years; Cohort 4: Up to 2.5 years

  6. CBR According to RECIST 1.1 by Investigator's Assessment

    CBR was the percentage of participants with the best overall response of CR, PR,or durable SD (SD ≥ 6 months after first dose) by investigator-assessed tumor response using RECIST 1.1 criteria.CR:Disappearance of all target and non-target lesions;\& normalization of tumor marker levels initially above upper limits of normal;PR:\>30% decrease in sum of LD of target lesions,taking as reference the baseline sum LD. SD:Neither sufficient shrinkage for PR nor sufficient increase for PD,taking reference of smallest sum LD since treatment started or ≥ 1 non-target lesions with maintenance of tumor marker level above normal limits.PD: Increase of \>20% in sum of diameters of target lesions,taking reference of smallest sum(this includes baseline sum if smallest on study),the sum must also demonstrate an absolute increase of more than 5 mm or of ≥ 1 new non-target lesions and/or unequivocal progression of existing non-target lesions.Two-sided CI was based on Clopper-Pearson method.

    Time frame: Cohort 1: Up to 5.3 years; Cohort 2: Up to 3.4 years; Cohort 3: Up to 3.3 years; Cohort 4: Up to 2.5 years

  7. PFS According to RECIST 1.1 by Investigator's Assessment

    PFS was defined as the time from the first dose until objective tumor progression or death from any cause, whichever comes first. Responses are based on the investigator-assessed tumor response using RECIST 1.1 criteria. Disease progression was defined as an increase of \>20% in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition, the sum must also demonstrate an absolute increase of more than 5 mm or the appearance ≥ 1 new non-target lesions and/or unequivocal progression of existing non-target lesions. PFS was estimated using Kaplan-Meier estimate. The 95% CI for median was computed by Brookmeyer-Crowley method.

    Time frame: Cohort 1: Up to 5.3 years; Cohort 2: Up to 3.4 years; Cohort 3: Up to 3.3 years; Cohort 4: Up to 2.5 years

  8. Overall Survival (OS)

    OS was defined as the interval from the first dose date of drug to death from any cause. OS was estimated using Kaplan-Meier estimate. The 95% CI for median was computed by Brookmeyer-Crowley method.

    Time frame: Cohort 1: Up to 5.3 years; Cohort 2: Up to 3.4 years; Cohort 3: Up to 3.3 years; Cohort 4: Up to 2.5 years

  9. Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)

    A TEAE was defined as any AE with an onset date on or after the study drug start date and no later than 30 days after last dose of study drug or the day before initiation of subsequent therapy, whichever comes first.

    Time frame: Up to 7.2 years

  10. Percentage of Participants Experiencing Clinically Significant Laboratory Abnormalities

    A treatment-emergent laboratory abnormality was defined as any value that increased at least 1 toxicity grade from baseline during the treatment-emergent period.

    Time frame: Up to 7.2 years

  11. Pharmacokinetic (PK) Parameter: Cmax of Total SN-38

    Cmax was defined as the maximum observed concentration of total SN-38 (the active metabolite of sacituzumab Govitecan-hziy). Cycle length=21 days.

    Time frame: Cohort 1: Post dose: Day 1 of Cycles 1,2,3,7,11,17,23,29,35,41,47; Cohort 2: Post dose: Day 1 of Cycles 1,2,3,7,11,17; Cohort 3: Post dose: Day 1 of Cycles 1,2,3,7,11,17,23,29,35,41,47,53; Cohort 4: Post dose: Day 1 of Cycles 1,2,3,7,11,17,23,29

  12. PK Parameter: Cmax of Free SN-38

    Cmax was defined as the maximum observed concentration of free SN-38 (the active metabolite of sacituzumab Govitecan-hziy). Cycle length=21 days.

    Time frame: Cohort 1: Post dose: Day 1 of Cycles 1,2,3,7,11,17,23,29,35,41,47; Cohort 2: Post dose: Day 1 of Cycles 1,2,3,7,11,17; Cohort 3: Post dose: Day 1 of Cycles 1,2,3,7,11,17,23,29,35,41,47,53; Cohort 4: Post dose: Day 1 of Cycles 1,2,3,7,11,17,23,29

  13. PK Parameter: Cmax of Total Antibody

    Cmax was defined as the maximum observed concentration of total antibody of SG \[hRS7 immunoglobulin (IgG) and hRS7-SN-38\]. Cycle length=21 days.

    Time frame: Cohort 1: Post dose: Day 1 of Cycles 1,2,3,7,11,17,23,29,35,41,47; Cohort 2: Post dose: Day 1 of Cycles 1,2,3,7,11,17; Cohort 3: Post dose: Day 1 of Cycles 1,2,3,7,11,17,23,29,35,41,47,53; Cohort 4: Post dose: Day 1 of Cycles 1,2,3,7,11,17,23,29

  14. PK Parameter: Ctrough of Total SN-38

    Ctrough was defined as concentration at the end of the dosing interval of total SN-38 (the active metabolite of sacituzumab Govitecan-hziy). Cycle length=21 days; C=Cohort; D=Day; EOT=End of Treatment; PD=predose; SFU=Safety Follow-up (up to 30 days after EOT date)

    Time frame: C1:PD,D1:Cycles1,2,3,7,11,17,23,29,35,41,47,EOT(Upto 38.7months)&SFU;C2:PD,D1:Cycles1,2,3,7,11,17,EOT(Upto 12.3months)&SFU;C3:PD,D1:Cycles1,2,3,7,11,17,23,29,35,41,47,53,EOT(Upto 40.0months)&SFU;C4:PD,D1:Cycles1,2,3,7,11,17,23,29,EOT(Upto 29.3months)&SFU

  15. PK Parameter: Ctrough of Free SN-38

    Ctrough was defined as concentration at the end of the dosing interval of free SN-38 (the active metabolite of sacituzumab Govitecan-hziy). Cycle length=21 days; C=Cohort; D=Day; EOT=End of Treatment; PD=predose; SFU=Safety Follow-up (up to 30 days after EOT date)

    Time frame: C1:PD,D1:Cycles1,2,3,7,11,17,23,29,35,41,47,EOT(Upto 38.7months)&SFU;C2:PD,D1:Cycles1,2,3,7,11,17,EOT(Upto 12.3months)&SFU;C3:PD,D1:Cycles1,2,3,7,11,17,23,29,35,41,47,53,EOT(Upto 40.0months)&SFU;C4:PD,D1:Cycles1,2,3,7,11,17,23,29,EOT(Upto 29.3months)&SFU

  16. PK Parameter: Ctrough of Total Antibody

    Ctrough was defined as concentration at the end of the dosing interval of total antibody of SG \[hRS7 immunoglobulin (IgG) and hRS7-SN-38\]. Cycle length=21 days; C=Cohort; D=Day; EOT=End of Treatment; PD=predose; SFU=Safety Follow-up (up to 30 days after EOT date)

    Time frame: C1:PD,D1:Cycles1,2,3,7,11,17,23,29,35,41,47,EOT(Upto 38.7months)&SFU;C2:PD,D1:Cycles1,2,3,7,11,17,EOT(Upto 12.3months)&SFU;C3:PD,D1:Cycles1,2,3,7,11,17,23,29,35,41,47,53,EOT(Upto 40.0months)&SFU;C4:PD,D1:Cycles1,2,3,7,11,17,23,29,EOT(Upto 29.3months)&SFU

  17. Percentage of Participants With Positive Anti-SG Antibodies

    Cycle length=21 days; C=Cohort; D=Day; EOT=End of Treatment; PD=predose; SFU=Safety Follow-up (up to 30 days after EOT date)

    Time frame: C1:PD,D1:Cycles1,2,3,7,11,17,23,29,35,41,47,EOT(Upto 38.7months)&SFU;C2:PD,D1:Cycles1,2,3,7,11,17,EOT(Upto 12.3months)&SFU;C3:PD,D1:Cycles1,2,3,7,11,17,23,29,35,41,47,53,EOT(Upto 40.0months)&SFU;C4:PD,D1:Cycles1,2,3,7,11,17,23,29,EOT(Upto 29.3months)&SFU

07

Results

Posted Jan 30, 2026

Participant flow

Participants were enrolled at study sites in the United States, France, Australia, Hong Kong, Spain, Taiwan, Canada, and Belgium.

Participant flow — Overall Study
MilestoneCohort 1 Group 1: NSCLC [Adenocarcinoma + Squamous Cell Carcinoma (SCC)]Cohort 1 Group 2: NSCLC (Adenocarcinoma)Cohort 1 Group 3: NSCLC (SCC)Cohort 2: Head And Neck Squamous Cell Carcinoma (HNSCC)Cohort 3: Endometrial Cancer (EC)Cohort 4: Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Started313431434143
Completed000000
Not completed313431434143
Withdrew: Death142325312832
Withdrew: Still on study062478
Withdrew: Reason not specified1631000
Withdrew: Withdrawal by subject123743
Withdrew: Lost to follow-up000120

Outcome measures

PrimaryObjective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by Investigator's Assessment

ORR was defined as the percentage of participants who had the best overall response of either complete response (CR) or partial response (PR). Responses are based on the investigator-assessed tumor response using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) criteria for each histologic cohort. CR: Disappearance of all target and non-target lesions; and normalization of tumor marker levels initially above upper limits of normal; PR: \>30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. The ORR rate was calculated with a two-sided exact 95% CI using the Clopper-Pearson method. Percentages are rounded off.

Time frame:
Cohort 1: Up to 5.3 years; Cohort 2: Up to 3.4 years; Cohort 3: Up to 3.3 years; Cohort 4: Up to 2.5 years
Reported as:
Number · percentage of participants
Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by Investigator's Assessment
percentage of participantsCohort 1 Group 1: NSCLC [Adenocarcinoma + SCC]Cohort 1 Group 2: NSCLC (Adenocarcinoma)Cohort 1 Group 3: NSCLC (SCC)Cohort 2: HNSCCCohort 3: ECCohort 4: ES-SCLC
Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by Investigator's Assessment12.9 (3.6 to 29.8)5.9 (0.7 to 19.7)6.5 (0.8 to 21.4)16.3 (6.8 to 30.7)26.8 (14.2 to 42.9)44.2 (29.1 to 60.1)
SecondaryORR According to RECIST 1.1 by Blinded Independent Central Review (BICR) Assessment

ORR was defined as the percentage of participants who had the best overall response of either CR or PR. Responses are based on BICR assessment using RECIST 1.1 criteria for each histologic cohort. CR: Disappearance of all target and non-target lesions; and normalization of tumor marker levels initially above upper limits of normal; PR: \>30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD. The ORR rate was calculated with a two-sided exact 95% CI using the Clopper-Pearson method.

Time frame:
Cohort 1: Up to 5.3 years; Cohort 2: Up to 3.4 years; Cohort 3: Up to 3.3 years; Cohort 4: Up to 2.5 years
Reported as:
Number · percentage of participants
ORR According to RECIST 1.1 by Blinded Independent Central Review (BICR) Assessment
percentage of participantsCohort 1 Group 1: NSCLC [Adenocarcinoma + SCC]Cohort 1 Group 2: NSCLC (Adenocarcinoma)Cohort 1 Group 3: NSCLC (SCC)Cohort 2: HNSCCCohort 3: ECCohort 4: ES-SCLC
ORR According to RECIST 1.1 by Blinded Independent Central Review (BICR) Assessment3.2 (0.1 to 16.7)8.8 (1.9 to 23.7)16.1 (5.5 to 33.7)18.6 (8.4 to 33.4)24.4 (12.4 to 40.3)44.2 (29.1 to 60.1)
SecondaryDuration of Response (DOR) According to RECIST 1.1 by BICR Assessment

DOR was the date of the first evaluation showing documented response, either PR or CR, to date of the first progression of disease (PD) or death from any cause,whichever comes first. Response are according to RECIST 1.1 by BICR for each histological cohort. CR: Disappearance of all target and non-target lesions; and normalization of tumor marker levels initially above upper limits of normal;PR: \>30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD. Disease progression was defined as an increase of \>20% in the sum of diameters of target lesions, taking as reference the smallest sum on study(this includes the baseline sum if that is the smallest on study). In addition, the sum must also demonstrate an absolute increase of more than 5 mm or the appearance of ≥ 1 new non-target lesions and/or unequivocal progression of existing non-target lesions. DOR was estimated using Kaplan-Meier estimate. The 95% CI was computed by Brookmeyer-Crowley method.

Time frame:
Cohort 1: Up to 5.3 years; Cohort 2: Up to 3.4 years; Cohort 3: Up to 3.3 years; Cohort 4: Up to 2.5 years
Reported as:
Median · months
Duration of Response (DOR) According to RECIST 1.1 by BICR Assessment
monthsCohort 1 Group 1: NSCLC [Adenocarcinoma + SCC]Cohort 1 Group 2: NSCLC (Adenocarcinoma)Cohort 1 Group 3: NSCLC (SCC)Cohort 2: HNSCCCohort 3: ECCohort 4: ES-SCLC
Duration of Response (DOR) According to RECIST 1.1 by BICR Assessment2.86 (NA to NA)22.08 (10.55 to NA)4.70 (2.10 to NA)8.67 (2.83 to NA)16.00 (2.76 to NA)6.01 (2.92 to 10.22)
SecondaryClinical Benefit Rate (CBR) According to RECIST 1.1 by BICR Assessment

CBR was percentage of participants with best overall response of CR, PR,or durable stable disease (SD) (SD ≥ 6 months after first dose). Responses are according to RECIST 1.1 by BICR.CR: Disappearance of all target and non-target lesions;\& normalization of tumor marker levels initially above upper limits of normal;PR:\>30% decrease in sum of LD of target lesions, taking as reference the baseline sum LD. SD:Neither sufficient shrinkage for PR nor sufficient increase for PD, taking reference of smallest sum LD since treatment started or ≥ 1 non-target lesions with maintenance of tumor marker level above normal limits.PD: Increase of \>20% in sum of diameters of target lesions, taking reference of smallest sum(this includes baseline sum if smallest on study), the sum must also demonstrate an absolute increase of more than 5 mm or of ≥ 1 new non-target lesions and/or unequivocal progression of existing non-target lesions. Two-sided CI was based on Clopper-Pearson method.

Time frame:
Cohort 1: Up to 5.3 years; Cohort 2: Up to 3.4 years; Cohort 3: Up to 3.3 years; Cohort 4: Up to 2.5 years
Reported as:
Number · percentage of participants
Clinical Benefit Rate (CBR) According to RECIST 1.1 by BICR Assessment
percentage of participantsCohort 1 Group 1: NSCLC [Adenocarcinoma + SCC]Cohort 1 Group 2: NSCLC (Adenocarcinoma)Cohort 1 Group 3: NSCLC (SCC)Cohort 2: HNSCCCohort 3: ECCohort 4: ES-SCLC
Clinical Benefit Rate (CBR) According to RECIST 1.1 by BICR Assessment29.0 (14.2 to 48.0)23.5 (10.7 to 41.2)19.4 (7.5 to 37.5)27.9 (15.3 to 43.7)39.0 (24.2 to 55.5)46.5 (31.2 to 62.3)
SecondaryProgression-free Survival (PFS) According to RECIST 1.1 by BICR Assessment

PFS was defined as the time from the first dose until objective tumor progression or death from any cause, whichever comes first. Responses are according to RECIST 1.1 by BICR. Disease progression was defined as an increase of \>20% in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition, the sum must also demonstrate an absolute increase of more than 5 mm or the appearance ≥ 1 new non-target lesions and/or unequivocal progression of existing non-target lesions. PFS was estimated using Kaplan-Meier estimate. The 95% CI for median was computed by Brookmeyer-Crowley method.

Time frame:
Cohort 1: Up to 5.3 years; Cohort 2: Up to 3.4 years; Cohort 3: Up to 3.3 years; Cohort 4: Up to 2.5 years
Reported as:
Median · months
Progression-free Survival (PFS) According to RECIST 1.1 by BICR Assessment
monthsCohort 1 Group 1: NSCLC [Adenocarcinoma + SCC]Cohort 1 Group 2: NSCLC (Adenocarcinoma)Cohort 1 Group 3: NSCLC (SCC)Cohort 2: HNSCCCohort 3: ECCohort 4: ES-SCLC
Progression-free Survival (PFS) According to RECIST 1.1 by BICR Assessment4.11 (2.50 to 7.52)4.24 (2.27 to 7.59)2.73 (1.41 to 5.49)3.25 (1.74 to 6.47)5.55 (2.79 to 9.59)4.40 (3.19 to 6.67)
SecondaryDOR According to RECIST 1.1 by Investigator's Assessment

DOR was the date of the first evaluation showing documented response, either PR or CR, to date of the first PD or death from any cause, whichever comes first. Responses are based on investigator-assessed tumor response by RECIST 1.1 criteria for each histological cohort.CR:Disappearance of all target and non-target lesions;and normalization of tumor marker levels initially above upper limits of normal;PR:\>30% decrease in the sum of the LD of target lesions,taking as reference the baseline sum LD. Disease progression was defined as increase of \>20% in sum of diameters of target lesions, taking as reference the smallest sum on study(this includes the baseline sum if that is the smallest on study).In addition, the sum must also demonstrate an absolute increase of more than 5 mm or the appearance of ≥ 1 new non-target lesions and/or unequivocal progression of existing non-target lesions. DOR was estimated using Kaplan-Meier estimate. The 95% CI was computed by Brookmeyer-Crowley method.

Time frame:
Cohort 1: Up to 5.3 years; Cohort 2: Up to 3.4 years; Cohort 3: Up to 3.3 years; Cohort 4: Up to 2.5 years
Reported as:
Median · months
DOR According to RECIST 1.1 by Investigator's Assessment
monthsCohort 1 Group 1: NSCLC [Adenocarcinoma + SCC]Cohort 1 Group 2: NSCLC (Adenocarcinoma)Cohort 1 Group 3: NSCLC (SCC)Cohort 2: HNSCCCohort 3: ECCohort 4: ES-SCLC
DOR According to RECIST 1.1 by Investigator's Assessment8.56 (6.41 to NA)21.09 (11.10 to NA)7.87 (6.05 to NA)4.21 (2.60 to 8.67)9.92 (2.79 to NA)6.31 (3.52 to 10.22)
SecondaryCBR According to RECIST 1.1 by Investigator's Assessment

CBR was the percentage of participants with the best overall response of CR, PR,or durable SD (SD ≥ 6 months after first dose) by investigator-assessed tumor response using RECIST 1.1 criteria.CR:Disappearance of all target and non-target lesions;\& normalization of tumor marker levels initially above upper limits of normal;PR:\>30% decrease in sum of LD of target lesions,taking as reference the baseline sum LD. SD:Neither sufficient shrinkage for PR nor sufficient increase for PD,taking reference of smallest sum LD since treatment started or ≥ 1 non-target lesions with maintenance of tumor marker level above normal limits.PD: Increase of \>20% in sum of diameters of target lesions,taking reference of smallest sum(this includes baseline sum if smallest on study),the sum must also demonstrate an absolute increase of more than 5 mm or of ≥ 1 new non-target lesions and/or unequivocal progression of existing non-target lesions.Two-sided CI was based on Clopper-Pearson method.

Time frame:
Cohort 1: Up to 5.3 years; Cohort 2: Up to 3.4 years; Cohort 3: Up to 3.3 years; Cohort 4: Up to 2.5 years
Reported as:
Number · percentage of participants
CBR According to RECIST 1.1 by Investigator's Assessment
percentage of participantsCohort 1 Group 1: NSCLC [Adenocarcinoma + SCC]Cohort 1 Group 2: NSCLC (Adenocarcinoma)Cohort 1 Group 3: NSCLC (SCC)Cohort 2: HNSCCCohort 3: ECCohort 4: ES-SCLC
CBR According to RECIST 1.1 by Investigator's Assessment32.3 (16.7 to 51.4)20.6 (8.7 to 37.9)16.1 (5.5 to 33.7)30.2 (17.2 to 46.1)41.5 (26.3 to 57.9)48.8 (33.3 to 64.5)
SecondaryPFS According to RECIST 1.1 by Investigator's Assessment

PFS was defined as the time from the first dose until objective tumor progression or death from any cause, whichever comes first. Responses are based on the investigator-assessed tumor response using RECIST 1.1 criteria. Disease progression was defined as an increase of \>20% in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition, the sum must also demonstrate an absolute increase of more than 5 mm or the appearance ≥ 1 new non-target lesions and/or unequivocal progression of existing non-target lesions. PFS was estimated using Kaplan-Meier estimate. The 95% CI for median was computed by Brookmeyer-Crowley method.

Time frame:
Cohort 1: Up to 5.3 years; Cohort 2: Up to 3.4 years; Cohort 3: Up to 3.3 years; Cohort 4: Up to 2.5 years
Reported as:
Median · months
PFS According to RECIST 1.1 by Investigator's Assessment
monthsCohort 1 Group 1: NSCLC [Adenocarcinoma + SCC]Cohort 1 Group 2: NSCLC (Adenocarcinoma)Cohort 1 Group 3: NSCLC (SCC)Cohort 2: HNSCCCohort 3: ECCohort 4: ES-SCLC
PFS According to RECIST 1.1 by Investigator's Assessment2.79 (1.48 to 7.82)3.78 (1.41 to 5.65)2.56 (1.41 to 5.49)4.14 (1.71 to 5.78)4.96 (2.76 to 9.82)4.40 (3.81 to 6.11)
SecondaryOverall Survival (OS)

OS was defined as the interval from the first dose date of drug to death from any cause. OS was estimated using Kaplan-Meier estimate. The 95% CI for median was computed by Brookmeyer-Crowley method.

Time frame:
Cohort 1: Up to 5.3 years; Cohort 2: Up to 3.4 years; Cohort 3: Up to 3.3 years; Cohort 4: Up to 2.5 years
Reported as:
Median · months
Overall Survival (OS)
monthsCohort 1 Group 1: NSCLC [Adenocarcinoma + SCC]Cohort 1 Group 2: NSCLC (Adenocarcinoma)Cohort 1 Group 3: NSCLC (SCC)Cohort 2: HNSCCCohort 3: ECCohort 4: ES-SCLC
Overall Survival (OS)14.26 (4.34 to 23.72)11.02 (4.24 to 20.47)7.29 (5.16 to 10.22)8.97 (7.52 to 12.22)14.95 (5.88 to 21.42)11.73 (6.57 to 14.72)
SecondaryPercentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)

A TEAE was defined as any AE with an onset date on or after the study drug start date and no later than 30 days after last dose of study drug or the day before initiation of subsequent therapy, whichever comes first.

Time frame:
Up to 7.2 years

Results for this outcome have not been posted.

SecondaryPercentage of Participants Experiencing Clinically Significant Laboratory Abnormalities

A treatment-emergent laboratory abnormality was defined as any value that increased at least 1 toxicity grade from baseline during the treatment-emergent period.

Time frame:
Up to 7.2 years

Results for this outcome have not been posted.

SecondaryPharmacokinetic (PK) Parameter: Cmax of Total SN-38

Cmax was defined as the maximum observed concentration of total SN-38 (the active metabolite of sacituzumab Govitecan-hziy). Cycle length=21 days.

Time frame:
Cohort 1: Post dose: Day 1 of Cycles 1,2,3,7,11,17,23,29,35,41,47; Cohort 2: Post dose: Day 1 of Cycles 1,2,3,7,11,17; Cohort 3: Post dose: Day 1 of Cycles 1,2,3,7,11,17,23,29,35,41,47,53; Cohort 4: Post dose: Day 1 of Cycles 1,2,3,7,11,17,23,29
Reported as:
Mean · nanograms per milliliter (ng/mL)
Pharmacokinetic (PK) Parameter: Cmax of Total SN-38
nanograms per milliliter (ng/mL)Cohort 1: NSCLCCohort 2: HNSCCCohort 3: ECCohort 4: ES-SCLC
Cycle 1 Day 14790 ± 11704410 ± 7344920 ± 10604670 ± 738
Cycle 2 Day 14420 ± 10104210 ± 8074640 ± 18404330 ± 760
Cycle 3 Day 14280 ± 14203930 ± 10804440 ± 11304150 ± 1040
Cycle 7 Day 14220 ± 9493750 ± 10904430 ± 9154210 ± 1160
Cycle 11 Day 14210 ± 12004720 ± 12104390 ± 10304250 ± 1390
Cycle 17 Day 14620 ± 8494700 ± 6474970 ± 9225510 ± 783
Cycle 23 Day 15140 ± 1090—4880 ± 10505420 ± 912
Cycle 29 Day 14580 ± 679—4720 ± 4995520 ± 424
Cycle 35 Day 14360 ± 1100—4110 ± 898—
Cycle 41 Day 15230 ± 1150—5450 ± NA—
Cycle 47 Day 14260 ± 1610—4580 ± NA—
Cycle 53 Day 1——5210 ± NA—
SecondaryPK Parameter: Cmax of Free SN-38

Cmax was defined as the maximum observed concentration of free SN-38 (the active metabolite of sacituzumab Govitecan-hziy). Cycle length=21 days.

Time frame:
Cohort 1: Post dose: Day 1 of Cycles 1,2,3,7,11,17,23,29,35,41,47; Cohort 2: Post dose: Day 1 of Cycles 1,2,3,7,11,17; Cohort 3: Post dose: Day 1 of Cycles 1,2,3,7,11,17,23,29,35,41,47,53; Cohort 4: Post dose: Day 1 of Cycles 1,2,3,7,11,17,23,29
Reported as:
Mean · ng/mL
PK Parameter: Cmax of Free SN-38
ng/mLCohort 1: NSCLCCohort 2: HNSCCCohort 3: ECCohort 4: ES-SCLC
Cycle 1 Day 165.4 ± 23.5200 ± 38694.5 ± 14378.5 ± 60.6
Cycle 2 Day 167.0 ± 40.294.9 ± 16070.2 ± 69.187.1 ± 65.8
Cycle 3 Day 1107 ± 27746.8 ± 17.262.5 ± 41.174.4 ± 75.9
Cycle 7 Day 164.6 ± 26.170.7 ± 50.163.8 ± 57.278.7 ± 63.3
Cycle 11 Day 154.6 ± 11.157.1 ± 29.859.3 ± 54.051.6 ± 25.2
Cycle 17 Day 156.6 ± 11.052.1 ± 18.173.3 ± 37.674.6 ± 35.2
Cycle 23 Day 172.8 ± 35.9—57.3 ± 21.253.0 ± 17.3
Cycle 29 Day 167.0 ± 23.0—158 ± 140170 ± 138
Cycle 35 Day 169.4 ± 51.1—90.4 ± 81.3—
Cycle 41 Day 176.1 ± 32.3—158 ± NA—
Cycle 47 Day 141.9 ± 8.77—369 ± NA—
Cycle 53 Day 1——239 ± NA—
SecondaryPK Parameter: Cmax of Total Antibody

Cmax was defined as the maximum observed concentration of total antibody of SG \[hRS7 immunoglobulin (IgG) and hRS7-SN-38\]. Cycle length=21 days.

Time frame:
Cohort 1: Post dose: Day 1 of Cycles 1,2,3,7,11,17,23,29,35,41,47; Cohort 2: Post dose: Day 1 of Cycles 1,2,3,7,11,17; Cohort 3: Post dose: Day 1 of Cycles 1,2,3,7,11,17,23,29,35,41,47,53; Cohort 4: Post dose: Day 1 of Cycles 1,2,3,7,11,17,23,29
Reported as:
Mean · ng/mL
PK Parameter: Cmax of Total Antibody
ng/mLCohort 1: NSCLCCohort 2: HNSCCCohort 3: ECCohort 4: ES-SCLC
Cycle 1 Day 1232000 ± 79200209000 ± 54700249000 ± 77700222000 ± 49400
Cycle 2 Day 1245000 ± 79700234000 ± 98700258000 ± 114000231000 ± 73000
Cycle 3 Day 1260000 ± 108000234000 ± 80600294000 ± 114000240000 ± 82100
Cycle 7 Day 1272000 ± 139000245000 ± 108000305000 ± 116000260000 ± 107000
Cycle 11 Day 1287000 ± 120000330000 ± 114000339000 ± 123000315000 ± 132000
Cycle 17 Day 1313000 ± 95800369000 ± 179000338000 ± 127000380000 ± 128000
Cycle 23 Day 1356000 ± 145000—313000 ± 104000473000 ± 45300
Cycle 29 Day 1227000 ± 218000—360000 ± 108000506000 ± NA
Cycle 35 Day 1304000 ± 63700—286000 ± 137000—
Cycle 41 Day 1282000 ± 66500—434000 ± NA—
Cycle 47 Day 1257000 ± 47400—283000 ± NA—
Cycle 53 Day 1——281000 ± NA—
SecondaryPK Parameter: Ctrough of Total SN-38

Ctrough was defined as concentration at the end of the dosing interval of total SN-38 (the active metabolite of sacituzumab Govitecan-hziy). Cycle length=21 days; C=Cohort; D=Day; EOT=End of Treatment; PD=predose; SFU=Safety Follow-up (up to 30 days after EOT date)

Time frame:
C1:PD,D1:Cycles1,2,3,7,11,17,23,29,35,41,47,EOT(Upto 38.7months)&SFU;C2:PD,D1:Cycles1,2,3,7,11,17,EOT(Upto 12.3months)&SFU;C3:PD,D1:Cycles1,2,3,7,11,17,23,29,35,41,47,53,EOT(Upto 40.0months)&SFU;C4:PD,D1:Cycles1,2,3,7,11,17,23,29,EOT(Upto 29.3months)&SFU
Reported as:
Mean · ng/mL
PK Parameter: Ctrough of Total SN-38
ng/mLCohort 1: NSCLCCohort 2: HNSCCCohort 3: ECCohort 4: ES-SCLC
Cycle 1 Day 1NA ± NANA ± NANA ± NANA ± NA
Cycle 2 Day 1NA ± NANA ± NANA ± NANA ± NA
Cycle 3 Day 1NA ± NANA ± NANA ± NANA ± NA
Cycle 7 Day 1NA ± NANA ± NANA ± NANA ± NA
Cycle 11 Day 1NA ± NANA ± NANA ± NANA ± NA
Cycle 17 Day 110.1 ± 4.059.78 ± 2.6610.8 ± 5.279.69 ± 3.46
Cycle 23 Day 1NA ± NA—NA ± NA10.1 ± 2.99
Cycle 29 Day 1NA ± NA—21.0 ± 24.46.68 ± NA
Cycle 35 Day 17.00 ± 1.78—NA ± NA—
Cycle 41 Day 1NA ± NA—6.61 ± NA—
Cycle 47 Day 1NA ± NA—6.12 ± NA—
Cycle 53 Day 1——7.55 ± NA—
EOTNA ± NANA ± NANA ± NANA ± NA
SFUNA ± NANA ± NANA ± NANA ± NA
SecondaryPK Parameter: Ctrough of Free SN-38

Ctrough was defined as concentration at the end of the dosing interval of free SN-38 (the active metabolite of sacituzumab Govitecan-hziy). Cycle length=21 days; C=Cohort; D=Day; EOT=End of Treatment; PD=predose; SFU=Safety Follow-up (up to 30 days after EOT date)

Time frame:
C1:PD,D1:Cycles1,2,3,7,11,17,23,29,35,41,47,EOT(Upto 38.7months)&SFU;C2:PD,D1:Cycles1,2,3,7,11,17,EOT(Upto 12.3months)&SFU;C3:PD,D1:Cycles1,2,3,7,11,17,23,29,35,41,47,53,EOT(Upto 40.0months)&SFU;C4:PD,D1:Cycles1,2,3,7,11,17,23,29,EOT(Upto 29.3months)&SFU
Reported as:
Mean · ng/mL
PK Parameter: Ctrough of Free SN-38
ng/mLCohort 1: NSCLCCohort 2: HNSCCCohort 3: ECCohort 4: ES-SCLC
Cycle 1 Day 1NA ± NANA ± NANA ± NANA ± NA
Cycle 2 Day 1NA ± NANA ± NANA ± NANA ± NA
Cycle 3 Day 1NA ± NANA ± NANA ± NANA ± NA
Cycle 7 Day 1NA ± NANA ± NANA ± NANA ± NA
Cycle 11 Day 1NA ± NANA ± NANA ± NANA ± NA
Cycle 17 Day 1NA ± NANA ± NANA ± NANA ± NA
Cycle 23 Day 1NA ± NA—NA ± NANA ± NA
Cycle 29 Day 1NA ± NA—NA ± NANA ± NA
Cycle 35 Day 1NA ± NA—NA ± NA—
Cycle 41 Day 1NA ± NA—NA ± NA—
Cycle 47 Day 1NA ± NA—NA ± NA—
Cycle 53 Day 1——NA ± NA—
EOTNA ± NANA ± NANA ± NANA ± NA
SFUNA ± NANA ± NANA ± NANA ± NA
SecondaryPK Parameter: Ctrough of Total Antibody

Ctrough was defined as concentration at the end of the dosing interval of total antibody of SG \[hRS7 immunoglobulin (IgG) and hRS7-SN-38\]. Cycle length=21 days; C=Cohort; D=Day; EOT=End of Treatment; PD=predose; SFU=Safety Follow-up (up to 30 days after EOT date)

Time frame:
C1:PD,D1:Cycles1,2,3,7,11,17,23,29,35,41,47,EOT(Upto 38.7months)&SFU;C2:PD,D1:Cycles1,2,3,7,11,17,EOT(Upto 12.3months)&SFU;C3:PD,D1:Cycles1,2,3,7,11,17,23,29,35,41,47,53,EOT(Upto 40.0months)&SFU;C4:PD,D1:Cycles1,2,3,7,11,17,23,29,EOT(Upto 29.3months)&SFU
Reported as:
Mean · ng/mL
PK Parameter: Ctrough of Total Antibody
ng/mLCohort 1: NSCLCCohort 2: HNSCCCohort 3: ECCohort 4: ES-SCLC
Cycle 1 Day 1NA ± NANA ± NANA ± NANA ± NA
Cycle 2 Day 135200 ± 2490052600 ± 4430046200 ± 3610036000 ± 26500
Cycle 3 Day 179500 ± 5820069000 ± 4070073500 ± 4910059500 ± 49600
Cycle 7 Day 189600 ± 8040070200 ± 51600107000 ± 6080065200 ± 44800
Cycle 11 Day 197500 ± 77400169000 ± 6770086900 ± 4680081600 ± 44300
Cycle 17 Day 1126000 ± 61500124000 ± 57700104000 ± 58800107000 ± 20400
Cycle 23 Day 180700 ± 56000—58200 ± 4170097300 ± 13800
Cycle 29 Day 183400 ± 42200—71100 ± 419008280086100 ± NA
Cycle 35 Day 194800 ± 17900—82800 ± 105000—
Cycle 41 Day 139200 ± 51600—2660 ± NA—
Cycle 47 Day 142100 ± 56200—2670 ± NA—
Cycle 53 Day 1——77200 ± NA—
EOT54800 ± 4310064600 ± 5150062100 ± 4380056300 ± 36900
SFU33000 ± 3330023800 ± 2300045800 ± 2880018900 ± 20800
SecondaryPercentage of Participants With Positive Anti-SG Antibodies

Cycle length=21 days; C=Cohort; D=Day; EOT=End of Treatment; PD=predose; SFU=Safety Follow-up (up to 30 days after EOT date)

Time frame:
C1:PD,D1:Cycles1,2,3,7,11,17,23,29,35,41,47,EOT(Upto 38.7months)&SFU;C2:PD,D1:Cycles1,2,3,7,11,17,EOT(Upto 12.3months)&SFU;C3:PD,D1:Cycles1,2,3,7,11,17,23,29,35,41,47,53,EOT(Upto 40.0months)&SFU;C4:PD,D1:Cycles1,2,3,7,11,17,23,29,EOT(Upto 29.3months)&SFU
Reported as:
Number · percentage of participants
Percentage of Participants With Positive Anti-SG Antibodies
percentage of participantsCohort 1 Group 1: NSCLC [Adenocarcinoma + SCC]Cohort 1 Group 2: NSCLC (Adenocarcinoma)Cohort 1 Group 3: NSCLC (SCC)Cohort 2: HNSCCCohort 3: ECCohort 4: ES-SCLC
Percentage of Participants With Positive Anti-SG Antibodies03.03.44.72.44.7

Adverse events

Collected over All-Cause Mortality and Adverse Events: Up to 5.3 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1 Group 1: NSCLC [Adenocarcinoma + SCC]26/31 (83.9%)15/31 (48.4%)30/31 (96.8%)
Cohort 1 Group 2: NSCLC (Adenocarcinoma)27/34 (79.4%)11/34 (32.4%)34/34 (100%)
Cohort 1 Group 3: NSCLC (SCC)28/31 (90.3%)13/31 (41.9%)30/31 (96.8%)
Cohort 2: HNSCC35/43 (81.4%)13/43 (30.2%)43/43 (100%)
Cohort 3: EC30/41 (73.2%)19/41 (46.3%)40/41 (97.6%)
Cohort 4: ES-SCLC32/43 (74.4%)22/43 (51.2%)43/43 (100%)
Most frequent serious events
Showing 10 of 108
Most frequent serious events
EventCohort 1 Group 1: NSCLC [Adenocarcinoma + SCC]Cohort 1 Group 2: NSCLC (Adenocarcinoma)Cohort 1 Group 3: NSCLC (SCC)Cohort 2: HNSCCCohort 3: ECCohort 4: ES-SCLC
Febrile neutropeniaBlood and lymphatic system disorders1/311/342/311/437/413/43
PneumoniaInfections and infestations1/310/344/311/432/412/43
DiarrhoeaGastrointestinal disorders1/311/342/310/435/410/43
DyspnoeaRespiratory, thoracic and mediastinal disorders1/312/343/310/430/411/43
HypokalaemiaMetabolism and nutrition disorders0/310/340/310/433/410/43
Acute kidney injuryRenal and urinary disorders1/310/340/310/433/410/43
LeukopeniaBlood and lymphatic system disorders2/311/340/310/430/410/43
Neutropenic colitisGastrointestinal disorders2/310/340/310/430/410/43
DeathGeneral disorders2/310/340/311/432/410/43
Pneumonia bacterialInfections and infestations0/310/342/310/430/410/43
Most frequent other events
Showing 10 of 107
Most frequent other events
EventCohort 1 Group 1: NSCLC [Adenocarcinoma + SCC]Cohort 1 Group 2: NSCLC (Adenocarcinoma)Cohort 1 Group 3: NSCLC (SCC)Cohort 2: HNSCCCohort 3: ECCohort 4: ES-SCLC
DiarrhoeaGastrointestinal disorders21/3117/3415/3120/4322/4133/43
AlopeciaSkin and subcutaneous tissue disorders14/3122/3413/3116/4317/4113/43
FatigueGeneral disorders15/3120/3418/3119/4324/4127/43
NauseaGastrointestinal disorders12/3120/3412/3120/4323/4117/43
NeutropeniaBlood and lymphatic system disorders16/3116/3415/3119/4324/4124/43
AnemiaBlood and lymphatic system disorders9/3112/346/3113/4319/4113/43
ConstipationGastrointestinal disorders11/3113/3411/316/4315/4118/43
Decreased appetiteMetabolism and nutrition disorders8/3110/3411/3111/433/4110/43
VomitingGastrointestinal disorders7/317/347/3115/4310/418/43
DyspnoeaRespiratory, thoracic and mediastinal disorders8/313/349/3111/432/413/43

Baseline characteristics

The Safety Analysis Set included all participants who received at least 1 dose of SG.

Age, Categorical
Age, Categorical(Participants)Cohort 1 Group 1: NSCLC [Adenocarcinoma + SCC]Cohort 1 Group 2: NSCLC (Adenocarcinoma)Cohort 1 Group 3: NSCLC (SCC)Cohort 2: HNSCCCohort 3: ECCohort 4: ES-SCLCTotal~(N=223)
<=18 years0000000
Between 18 and 65 years161614321517110
>=65 years151817112626113
Age, Continuous
Age, Continuous(years)Cohort 1 Group 1: NSCLC [Adenocarcinoma + SCC]Cohort 1 Group 2: NSCLC (Adenocarcinoma)Cohort 1 Group 3: NSCLC (SCC)Cohort 2: HNSCCCohort 3: ECCohort 4: ES-SCLCTotal~(N=223)
Mean65 ± 8.764 ± 10.565 ± 8.461 ± 6.866 ± 9.166 ± 8.264 ± 8.7
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1 Group 1: NSCLC [Adenocarcinoma + SCC]Cohort 1 Group 2: NSCLC (Adenocarcinoma)Cohort 1 Group 3: NSCLC (SCC)Cohort 2: HNSCCCohort 3: ECCohort 4: ES-SCLCTotal~(N=223)
Female15198104123116
Male16152333020107
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1 Group 1: NSCLC [Adenocarcinoma + SCC]Cohort 1 Group 2: NSCLC (Adenocarcinoma)Cohort 1 Group 3: NSCLC (SCC)Cohort 2: HNSCCCohort 3: ECCohort 4: ES-SCLCTotal~(N=223)
Hispanic or Latino0200226
Not Hispanic or Latino303129403436200
Unknown or Not Reported11235517
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort 1 Group 1: NSCLC [Adenocarcinoma + SCC]Cohort 1 Group 2: NSCLC (Adenocarcinoma)Cohort 1 Group 3: NSCLC (SCC)Cohort 2: HNSCCCohort 3: ECCohort 4: ES-SCLCTotal~(N=223)
Race — White232624332136163
Race — Black or African American63311216
Race — Asian05148220
Race — American Indian or Alaska Native0002204
Race — Native Hawaiian or Other Pacific Islander0001001
Race — Other or More Than One Race1020317
Race — Unknow or Not Reported10126212
Region of Enrollment
Region of Enrollment(Participants)Cohort 1 Group 1: NSCLC [Adenocarcinoma + SCC]Cohort 1 Group 2: NSCLC (Adenocarcinoma)Cohort 1 Group 3: NSCLC (SCC)Cohort 2: HNSCCCohort 3: ECCohort 4: ES-SCLCTotal~(N=223)
United States313226342822173
France00352212
Australia00114511
Hong Kong0211509
Spain0000099
Taiwan0001124
Canada0001113
Belgium0000022
08

Study locations

65 sites
09

References and documents

Publications

  • Santin AD, Corr BR, Spira A, Willmott L, Butrynski J, Tse KY, Patel J, Mekan S, Wu T, Lin KW, Kuo P, Dumbrava EE. Efficacy and Safety of Sacituzumab Govitecan in Patients With Advanced Solid Tumors (TROPiCS-03): Analysis in Patients With Advanced Endometrial Cancer. J Clin Oncol. 2024 Oct 10;42(29):3421-3429. doi: 10.1200/JCO.23.02767. Epub 2024 Jul 31. PubMed 39083724 ↗
  • Michel L, Jimeno A, Sukari A, Beck JT, Chiu J, Ahern E, Hilton J, Even C, Zanetta S, Mekan S, Patel J, Wu T, Dumbrava EE. Sacituzumab Govitecan in Patients with Relapsed/Refractory Advanced Head and Neck Squamous Cell Carcinoma: Results from the Phase II TROPiCS-03 Basket Study. Clin Cancer Res. 2025 Mar 3;31(5):832-838. doi: 10.1158/1078-0432.CCR-24-2523. PubMed 39665770 ↗
  • Dowlati A, Chiang AC, Cervantes A, Babu S, Hamilton E, Wong SF, Tazbirkova A, Sullivan IG, van Marcke C, Italiano A, Patel J, Mekan S, Wu T, Waqar SN. Phase 2 Open-Label Study of Sacituzumab Govitecan as Second-Line Therapy in Patients With Extensive-Stage SCLC: Results From TROPiCS-03. J Thorac Oncol. 2025 Jun;20(6):799-808. doi: 10.1016/j.jtho.2024.12.028. Epub 2025 Jan 2. PubMed 39755168 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2019 to primary completion in Jan 2025, 63 months.

Results were first posted in Jan 2026, 1 year after primary completion.

Of 88 industry-sponsored phase 2 interventional studies under Neoplasm Metastasis, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 63. This study's 63 months is above that.

Counting every sponsor, half of 443 studies reached it within 56 months; a quarter within 33 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2019
First posted
May 28, 2019
StartActual
Oct 15, 2019
Primary completionActual
Jan 15, 2025
CompletionEst.
Dec 2026
Results first posted
Jan 30, 2026
Last update
Apr 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03964727
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
May 28, 2019
Start date
Oct 15, 2019
Primary completion
Jan 15, 2025
Completion
Dec 2026 (estimated)
Results posted
Jan 30, 2026
Last update
Apr 28, 2026

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sacituzumab govitecan

Start the discussion